Summary

Report Scope
The current report provides detailed information on immunotherapy drugs. It analyzes the market trends with data from 2024, estimates for 2025 and projections of compound annual growth rates (CAGRs) from 2025 through 2030, including regional markets for immunotherapy drugs. This report highlights the current and future market potential and provides a detailed discussion on the competitive environment. The report will also cover regulatory scenarios, drivers, restraints and opportunities. Additionally, it covers market share data for key companies.
The market in this report is segmented by immunotherapy type into checkpoint inhibitors, monoclonal antibodies (mAbs) and cytokine therapy. MAbs are sub-segmented into naked mAbs, conjugated mAbs and bispecific mAbs. Checkpoint inhibitors are sub-segmented into programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3).
By application, the market is segmented into cancer, autoimmune diseases and chronic inflammatory diseases.
By region, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America. The regional segment will cover a detailed analysis of the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India. Market data is provided for 2024 the base year, with forecasts for 2025 and a forecast value for 2030.
The report aims to:
- Analyze types of immunotherapies.
- Analyze global market size and segmentation.
- Understand market constraints and drivers.
- Provide detailed market forecasts through 2030.
- Assess market shares, competitiveness and industry structure.
- Identify potential long-term impacts on the immunotherapy drug market.

Report Includes
- 88 data tables and 57 additional tables
- An overview of the global market for immunotherapy drugs
- In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, and forecasts for 2030, including projections of CAGRs through 2030
- Evaluation of the current market size and revenue growth prospects specific to the immunotherapy drugs, accompanied by a market share analysis by therapy type, application and region
- Description of immunotherapy and combination immunotherapy, and discussion of how it targets cell-mediated adaptive immunity
- Details of checkpoint inhibitors, monoclonal antibodies, interleukins and interferons; and coverage of innovative strategies and new targeted approaches for immunotherapy
- Analysis of the current and future demands in the global immunotherapy drugs, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
- Analysis of drivers, challenges and opportunities affecting the market’s growth
- Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
- Market share analysis of the key companies in the immunotherapy drugs, along with their research priorities, product portfolios, global rankings and the competitive landscape
- Profiles of major companies in industry, including F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, and Sanofi

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Overview
Macroeconomic Factor Analysis
Impact of U.S. Tariffs on the Pharmaceutical Industry
Healthcare Expenditure
Impact of GDP on the Pharma Sector
Porter's Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Threat of Substitutes
Competitiveness in the Industry
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Increasing Incidence of Chronic Diseases
Increasing R&D Spending by Market Players
Rise in Government Funding and Pharmaceutical R&D Spending
Market Restraints
High Cost of Immunotherapy Drugs
Rising Generic Competition
Lack of Skilled Professionals
Market Opportunities
Technological Advances in Immunotherapy
Potential in Immunotherapy
Chapter 4 Regulatory Landscape
Overview
U.S.
Europe
Asia-Pacific
Chapter 5 Emerging Technologies and Pipeline Analysis
Overview
AI and ML
Emergent Biomarkers
Genome Editing and CRISPR
Pipeline Analysis
Key Takeaways
Patent Analysis
Key Takeaways
Chapter 6 Market Segment Analysis
Segmentation Breakdown
Global Market for Immunotherapy Drugs, by Therapy Type
Key Takeaways
Monoclonal Antibodies
Checkpoint Inhibitors
Cytokines
Others
Global Immunotherapy Drug Market, by Application
Key Takeaways
Cancer
Autoimmune Diseases
Chronic Inflammatory Respiratory Condition
Geographic Breakdown
Global Market for Immunotherapy Drugs by Region
Key Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa
Chapter 7 Competitive Intelligence
Key Takeaways
Competitive Landscape
Company Share Analysis
Chapter 8 Sustainability in Immunotherapy Drugs Market: An ESG Perspective
Introduction to ESG
Sustainability in the Immunotherapy Drug Market
ESG Perspective
Environmental Impact
Social Impact
Governance Impact
ESG Risk Ratings
Conclusion
Chapter 9 Appendix
Methodology
Abbreviations
Sources
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GSK PLC.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO.INC.
NOVARTIS AG
PFIZER INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Emerging Players in the Immunotherapy Drugs Market

ページTOPに戻る

List of Tables/Graphs

List of Tables
Summary Table : Global Market for Immunotherapy Drugs, by Region, Through 2030
Table 1 : Health Expenditure
Table 2 : Rheumatoid Arthritis: Level 3 Cause, 2021
Table 3 : Average Price of Immunotherapy
Table 4 : List of Selected Clinical Trials Studies on Immunotherapy
Table 5 : List of Selected Recent Patents Related to Immunotherapy Drugs, January 2024–June 2025
Table 6 : Global Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 7 : Global Market for Monoclonal Antibodies in Immunotherapy Drugs, by Type, Through 2030
Table 8 : Global Market for Monoclonal Antibodies in Immunotherapy Drugs, by Region, Through 2030
Table 9 : FDA-Approved Immune Checkpoint Inhibitors, 2022
Table 10 : Global Market for Checkpoint Inhibitors in Immunotherapy Drugs, by Type, Through 2030
Table 11 : Global Market for Checkpoint Inhibitors in Immunotherapy Drugs, by Region, Through 2030
Table 12 : Global Market for Cytokines in Immunotherapy Drugs, by Type, Through 2030
Table 13 : Global Market for Cytokines in Immunotherapy Drugs, by Region, Through 2030
Table 14 : Players Investing in Oncolytic Virology
Table 15 : Approved CAR-T Products, 2017–2025
Table 16 : Global Market for Other Therapy Types in Immunotherapy Drugs, by Region, Through 2030
Table 17 : Global Market for Immunotherapy Drugs, by Application, Through 2030
Table 18 : Global Market for Immunotherapy Drugs in Cancer, by Region, Through 2030
Table 19 : Global Market for Immunotherapy Drugs in Autoimmune Diseases, by Region, Through 2030
Table 20 : Global Market for Immunotherapy Drugs in Chronic Inflammatory Respiratory Diseases, by Region, Through 2030
Table 21 : Global Market for Immunotherapy Drugs in Other Diseases, by Region, Through 2030
Table 22 : Global Market for Immunotherapy Drugs, by Region, Through 2030
Table 23 : North American Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 24 : North American Market for Immunotherapy Drugs, by Application, Through 2030
Table 25 : North American Market for Immunotherapy Drugs, by Country, Through 2030
Table 26 : U.S. Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 27 : U.S. Market for Immunotherapy Drugs, by Application, Through 2030
Table 28 : Canadian Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 29 : Canadian Market for Immunotherapy Drugs, by Application, Through 2030
Table 30 : Mexican Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 31 : Mexican Market for Immunotherapy Drugs, by Application, Through 2030
Table 32 : European Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 33 : European Market for Immunotherapy Drugs, by Application, Through 2030
Table 34 : European Market for Immunotherapy Drugs, by Country, Through 2030
Table 35 : German Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 36 : German Market for Immunotherapy Drugs, by Application, Through 2030
Table 37 : U.K. Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 38 : U.K. Market for Immunotherapy Drugs, by Application, Through 2030
Table 39 : French Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 40 : French Market for Immunotherapy Drugs, by Application, Through 2030
Table 41 : Italian Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 42 : Italian Market for Immunotherapy Drugs, by Application, Through 2030
Table 43 : Spanish Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 44 : Spanish Market for Immunotherapy Drugs, by Application, Through 2030
Table 45 : Rest of Europe Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 46 : Rest of Europe Market for Immunotherapy Drugs, by Application, Through 2030
Table 47 : Recently Approved Immunotherapies in Asian Countries, 2021–2024
Table 48 : Asia-Pacific Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 49 : Asia-Pacific Market for Immunotherapy Drugs, by Application, Through 2030
Table 50 : Asia-Pacific Market for Immunotherapy Drugs, by Country, Through 2030
Table 51 : Chinese Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 52 : Chinese Market for Immunotherapy Drugs, by Application, Through 2030
Table 53 : Japanese Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 54 : Japanese Market for Immunotherapy Drugs, by Application, Through 2030
Table 55 : Indian Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 56 : Indian Market for Immunotherapy Drugs, by Application, Through 2030
Table 57 : South Korean Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 58 : South Korean Market for Immunotherapy Drugs, by Application, Through 2030
Table 59 : Australian Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 60 : Australian Market for Immunotherapy Drugs, by Application, Through 2030
Table 61 : Rest of Asia-Pacific Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 62 : Rest of Asia-Pacific Market for Immunotherapy Drugs, by Application, Through 2030
Table 63 : South American Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 64 : South American Market for Immunotherapy Drugs, by Application, Through 2030
Table 65 : South American Market for Immunotherapy Drugs, by Country, Through 2030
Table 66 : Brazilian Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 67 : Brazilian Market for Immunotherapy Drugs, by Application, Through 2030
Table 68 : Argentine Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 69 : Argentine Market for Immunotherapy Drugs, by Application, Through 2030
Table 70 : Rest of South America Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 71 : Rest of South America Market for Immunotherapy Drugs, by Application, Through 2030
Table 72 : MEA Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 73 : MEA Market for Immunotherapy Drugs, by Application, Through 2030
Table 74 : MEA Market for Immunotherapy Drugs, by Sub-Region, Through 2030
Table 75 : Middle Eastern Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 76 : Middle Eastern Market for Immunotherapy Drugs, by Application, Through 2030
Table 77 : African Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 78 : African Market for Immunotherapy Drugs, by Application, Through 2030
Table 79 : News/Key Developments in the Immunotherapy Drug Market, 2023–2025
Table 80 : Key Focus Areas in ESG Metrics
Table 81 : ESG Rankings for Leading Companies in Immunotherapy Drugs Market, 2025*
Table 82 : Abbreviations Used in this Report
Table 83 : Report Sources
Table 84 : AbbVie Inc.: Company Snapshot
Table 85 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 86 : AbbVie Inc.: Product Portfolio
Table 87 : AbbVie Inc.: News/Key Developments, 2023-2025
Table 88 : Amgen Inc.: Company Snapshot
Table 89 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 90 : Amgen Inc.: Product Portfolio
Table 91 : Amgen Inc.: News/Key Developments, 2022-2025
Table 92 : AstraZeneca: Company Snapshot
Table 93 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 94 : AstraZeneca: Product Portfolio
Table 95 : AstraZeneca: News/Recent Developments, 2023-2024
Table 96 : Bristol-Myers Squibb Co.: Company Snapshot
Table 97 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2024
Table 98 : Bristol-Myers Squibb Co.: Product Portfolio
Table 99 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2025
Table 100 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 101 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 102 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 103 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2025
Table 104 : Gilead Sciences Inc.: Company Snapshot
Table 105 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 106 : Gilead Sciences Inc.: Product Portfolio
Table 107 : Gilead Sciences Inc.: News/Key Developments, 2023-2025
Table 108 : GSK Plc: Company Snapshot
Table 109 : GSK Plc: Financial Performance, FY 2023 and 2024
Table 110 : GSK Plc: Product Portfolio
Table 111 : GSK Plc: News/Key Developments, 2022-2025
Table 112 : Johnson & Johnson Services Inc.: Company Snapshot
Table 113 : Johnson & Johnson Services Inc.: Financial Performance, FY 2023 and 2024
Table 114 : Johnson & Johnson Services Inc.: Product Portfolio
Table 115 : Johnson & Johnson Services Inc.: News/Key Developments, 2022-2025
Table 116 : Lilly: Company Snapshot
Table 117 : Lilly: Financial Performance, FY 2023 and 2024
Table 118 : Lilly: Product Portfolio
Table 119 : Lilly: News/Key Development, 2022-2025
Table 120 : Merck & Co. Inc.: Company Snapshot
Table 121 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 122 : Merck & Co. Inc.: Product Portfolio
Table 123 : Merck & Co. Inc.: News/Key Developments, 2021-2025
Table 124 : Novartis AG: Company Snapshot
Table 125 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 126 : Novartis AG: Product Portfolio
Table 127 : Novartis AG: News/Key Developments, 2022-2024
Table 128 : Pfizer Inc.: Company Snapshot
Table 129 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 130 : Pfizer Inc.: Product Portfolio
Table 131 : Pfizer Inc.: News/Key Developments, 2022-2025
Table 132 : Sanofi: Company Snapshot
Table 133 : Sanofi: Financial Performance, FY 2023 and 2024
Table 134 : Sanofi: Product Portfolio
Table 135 : Sanofi: News/Key Developments, 2022–2025
Table 136 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 137 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2023 and 2024
Table 138 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 139 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023-2025
Table 140 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 141 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
Table 142 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 143 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2024- 2025
Table 144 : Some Emerging Players in the Immunotherapy Drugs Market